COMPANY PROFILE

Synerkine Pharma

Explore full profile

Synerkine Pharma is a developer of fusion proteins for the treatment of chronic pain

Naarden, NetherlandsFounded 2018Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Synerkine Pharma

Synerkine Pharma specializes in developing a novel class of therapeutics by leveraging the connections between cytokines to improve patient outcomes. The company operates in the biopharmaceutical sector, focusing on creating innovative treatments for inflammatory diseases. Synerkine Pharma collaborates with academic institutions like the University Medical Center Utrecht (UMCU) to advance its research and development efforts. The business model revolves around the development and commercialization of proprietary cytokine-based therapies, generating revenue through partnerships, grants, and eventual product sales. The primary clients include healthcare providers, research institutions, and pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Naarden, Netherlands
Employees: 6
Open positions: None listed
Dealroom signal: 59.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2023	$13M	$53M	Thuja Capital · Utrecht Health Seed Fund · InnovationQuarter Capital · Flerie Invest	↗
SERIES A✓Equity / VC	Dec 2021	$3.9M	$16M	Thuja Capital · Flerie Invest · Utrecht Holdings	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Synerkine Pharma website traffic

Latest recorded traffic for Synerkine Pharma is 690 monthly website visits, up 666.7% over the last three months. Synerkine Pharma's team declined 25% over the past year.

Latest monthly visits690 3-month web change+666.7% 1-year team growth-25%

Monthly website visitsDec 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LOLogomixLarge-scale genome engineering platform for cell therapy	Tokyo, Japan	Operational	10	$35M	$111M
BCBLOCKStrain Technology Corp.Developer of the first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry	Vancouver, Canada	Operational
SOSocatiSocati is the leading processor of THC-free full-spectrum hemp	Woodburn, United States	Operational
ABArcis BiotechnologyFast & convenient nucleic acid sample preservation and preparation. Prepare RNA & DNA for PCR/NGS in less than 3 minutes	Daresbury, United Kingdom	Operational
BIBioelectronicaA research-stage biotechnology company building next-generation digital tools for drug discovery, diagnostics, and cell sorting	Reno, United States	Operational
ABARCA biopharmaGenetically-targeted therapies for cardiovascular diseases	Westminster, United States	Acquired
SOSoftGeneticsResearchers and clinicians with software analysis tools for genetic analysis	State College, United States	Acquired
PLPlumCareAn Alameda, CA-based DNA advisory service for families	Alameda, United States	Operational